Авторские права: © 2026 принадлежат авторам. Лицензиат: РНИМУ им. Н.И. Пирогова.
Статья размещена в открытом доступе и распространяется на условиях лицензии Creative Commons Attribution (CC BY).

ОБЗОР

Этика ранней диагностики нейродегенеративных заболеваний в условиях онтологической неопределенности

Д. Ф. Абдуллаева
Информация об авторах

Российский национальный исследовательский медицинский университет имени Н. И. Пирогова (Пироговский Университет), Москва, Россия

Для корреспонденции: Диана Фейзудиновна Абдуллаева
ул. Островитянова, д. 1, г. Москва, 117997, Россия; ur.xednay@7avealludbaanaid

Информация о статье

Финансирование: исследование выполнено за счет гранта Российского научного фонда № 26-18-00593, https://rscf.ru/project/26-18-00593/.

Статья получена: 03.09.2026 Статья принята к печати: 20.09.2026 Опубликовано online: 16.11.2026
|
  1. Baviskar PS, Mahajan HS. Unveiling Alzheimer’s disease (1901– 2025): Historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies. Ageing Res Rev. 2026; 114: 102990. DOI: 10.1016/j.arr.2025.102990.
  2. World Health Organization. Parkinson disease. Fact sheet. Geneva: WHO; 2023 Aug 9. Available from: https://www.who. int/news-room/fact-sheets/detail/parkinson-disease (accessed: 13.07.2026).
  3. Roche Diagnostics. Elecsys ApoE4 biomarker test receives CE Mark approval. 2026 Mar 16. URL: https://www.prnewswire. com/news-releases/roche-receives-ce-mark-for-first-ivd-immunoassay-blood-test-to-identify-carriers-of-apoe4-a-genetic-variant-present-in-up-to-60-of-patients-diagnosed-with-alzheimers-disease-302714082.html. (accessed: 16.07.2026).
  4. Su D, et al. Projections for Prevalence of Parkinson’s Disease and its Driving Factors in 195 Countries and Territories to 2050: Modelling Study of Global Burden of Disease Study 2021. BMJ. 2025; 388: e080952. DOI: 10.1136/bmj-2024-080952.
  5. Genetic Testing Registry. National Library of Medicine (US). Alzheimer’s Disease, Familial, Plus APOE Panel. GTR Test Accession: GTR000613038.3. Updated 2025 Nov 7. URL: https://www.ncbi.nlm.nih.gov/gtr/tests/613038/. (accessed: 21.07.2026).
  6. Genetic Testing Registry. National Library of Medicine (US). Parkinson Disease and Parkinsonism Panel. GTR Test Accession: GTR000562149.5. Updated 2020 Sep 12. URL: https://www. ncbi.nlm.nih.gov/gtr/tests/562149.5/. (accessed: 21.07.2026).
  7. Genetic Testing Registry. National Library of Medicine (US). Parkinson’s Disease via the SNCA Gene. GTR Test Accession: GTR000556828.3. Updated 2020 Sep 09. URL: https:// www.ncbi.nlm.nih.gov/gtr/tests/classic/556828.3/. (accessed: 21.07.2026).
  8. Ni-Chung Lee, Chin-Hsien Lin, Yin-Hsiu Chien, Wuh-Liang Hwu. Genetic testing for adult-onset neurodegenerative diseases: A clinical perspective, Journal of the Formosan Medical Association. 2026; 125(Suppl. 1): 99–104. DOI: 10.1016/j.jfma.2026.01.021.
  9. Beauchamp T, Childress J. Principles of Biomedical Ethics: Marking Its Fortieth Anniversary. Am J Bioeth. 2019; 19(11): 9–12. DOI: 10.1080/15265161.2019.1665402.
  10. Deven K. Burks, Jane S. Paulsen, Ethical challenges to the responsible communication of individual results from observational neurodegeneration research. Developments in Neuroethics and Bioethics. Academic Press. 2026; 9: 199–234. DOI: 10.1016/bs.dnb.2026.02.009.
  11. Гребенщикова Е. Г. Биоэтические проблемы пресимптоматического генетического тестирования болезни Альцгеймера и болезни Паркинсона. Этическая мысль. 2025; 25(2): 155–164. DOI: 10.21146/2074-4870-2025-25-2-155-164.
  12. Schweda M, Kögel A, Bartels C, Wiltfang J, Schneider A, Schicktanz S. Prediction and Early Detection of Alzheimer’s Dementia: Professional Disclosure Practices and Ethical Attitudes. J Alzheimers Dis. 2018; 62(1): 145–155. DOI: 10.3233/JAD-170443.
  13. Goswami S, Hartz SM, Oliver A, et al. Research Participant Interest in Learning Results of Biomarker Tests for Alzheimer Disease. JAMA Netw Open. 2025; 8(5): e252919. Published 2025 May 1. DOI: 10.1001/jamanetworkopen.2025.2919.
  14. Jamal L, Schupmann W, Berkman BE. An ethical framework for genetic counseling in the genomic era. J Genet Couns. 2020 Oct; 29(5): 718–727. DOI: 10.1002/jgc4.1207.
  15. Baractari T, Evghenia, Ojovanu, Vitalie. Neurobioethics and the principle of confidentiality in neurodegenerative processes. In: Noi orizonturi in sanatatea mintala, Ed. Ediția 1, 20–23 octombrie 2025, Chişinău. Chişinău: Primex-Com. 2025; 40b.
  16. Nurmi SM, Halkoaho A, Moilanen J, Remes AM, Solje E. The ethical implications of genetic testing in neurodegenerative diseases: A systematic review. Scand J Caring Sci. 2021 Dec; 35(4): 1057–1074. DOI: 10.1111/scs.12932.
  17. Arias J, Blasco D, Prince AER, Largent EA. Legal Protections to Mitigate Discrimination due to Neurodegenerative Biomarker Status. Neurology. 2026; 107: e218296. DOI: 10.1212/ WNL.0000000000218296.
  18. Stites SD, Dedhia M, Harkins K, et al. Learning about a heightened genetic risk for dementia: Expected stigma is greater than experienced stigma. Psychology and Aging. 2026 Aug; 41(5): 613–625. DOI: 10.1037/pag0000970.
  19. Grouios A. Public reactions and perceptions associated with three neuro-degenerative diseases: Parkinson’s, Alzheimer’s and Multiple Sclerosis [Honours thesis]. Swinburne University of Technology; 2006. DOI: 10.25916/sut.26288608.
  20. Mattsson N, Brax D, Zetterberg H. To know or not to know: ethical issues related to early diagnosis of Alzheimer’s disease. Int J Alzheimers Dis. 2010 Jun 27; 2010: 841941. DOI: 10.4061/2010/841941.
  21. Kim SY, Karlawish J, Berkman BE. Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology. 2015 Apr 7; 84(14): 1488–94. DOI: 10.1212/WNL.0000000000001451.
  22. Bunnik EM, Smedinga M, Milne R, Georges J, Richard E, Schermer MHN. Ethical Frameworks for Disclosure of Alzheimer Disease Biomarkers to Research Participants: Conflicting Norms and a Nuanced Policy. Ethics Hum Res. 2022 Nov; 44(6): 2–13. DOI: 10.1002/eahr.500146.
  23. Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16; 90(3): 126–135. DOI: 10.1212/WNL.0000000000004826.
  24. Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024 Aug; 20(8): 5143–5169. DOI: 10.1002/alz.13859.
  25. Perlmutter D. Why Redefining Alzheimer’s as a “Biological” Condition Is Harmful, and Why the International Working Group Is Pushing Back [Internet]. 2025 Dec 3. Available from URL: https:// drperlmutter.com/redefining-alzheimers-biological-condition-harmful-international-working-group-pushing-back/ (accessed: 19.08.2026).
  26. Accorroni A, Clavien C, Frisoni GB. Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer’s Disease. Neurodegenerative Diseases. 2026 Jun 25; 1–33. DOI: 10.1159/000552764.
  27. Rossini PM, Pappalettera C. Should all MCI with Alzheimer’s biological diagnosis receive anti-amyloid therapy? Cell Death Dis. 2026; 17: 212. DOI: 10.1038/s41419-026-08456-z.
  28. Karneboge J, Haberstroh J, Geschke K, Perry J, Radenbach K, Jessen F, Rostamzadeh A. Facing the new diagnostic and treatment options of Alzheimer’s disease: The necessity of informed consent. Alzheimers Dement. 2025 Jan; 21(1): e14204. DOI: 10.1002/alz.14204.